Angiotensin-Converting Enzyme 2 in Health and Diseases
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".
Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 2018
Special Issue Editor
Special Issue Information
Dear Colleagues,
The renin–angiotensin system (RAS) plays an important role in maintaining body fluid and electrolyte homeostasis and blood pressure regulation. It has been more than 20 years since the discovery of angiotensin-converting enzyme 2 (ACE2), a key enzyme of RAS. ACE2 belongs to the angiotensin-converting enzyme family of dipeptidyl carboxydipeptidases, and converts angiotensin I to angiotensin 1–9, a nine-amino acid peptide with an antihypertrophic effect. ACE2 acts as a counter regulatory enzyme for ACE, cleaving angiotensin II to angiotensin 1–7 to act as a vasodilator and antiproliferation agent. Given its extensive presence in various organs and numerous physiological functions, ACE2 is associated with an array of disease pathologies related to cardiovascular, pulmonary and renal function and fertility, and more recently in SARS-Cov-2 infection; however, the full spectrum of its functions has not been fully elucidated. Moreover, fundamental questions remain about the role of ACE2 in other organs exhibiting moderate expression and its mechanism of action in regulating conditions such as inflammation, infection and brain function. The recent wave of literature on ACE2’s role in COVID-19 has overshadowed the important roles of ACE2 in other physiologies and pathophysiologies. The protective effects of ACE2 expression in systemic and pulmonary hypertension, cardiovascular diseases, diabetes, kidney injury, liver injury and brain function have been well-established in the last two decades of research. There has been a battery of humanized transgenic ACE2 animal models generated during COVID-19 pandemic, which can be used to appreciate the deeper mechanistic understanding of ACE2 physiology. This Special Issue, “ACE2 in health and diseases”, will cover articles describing the molecular aspects of ACE2 to advance our understanding of its roles in health and disease. We invite all the submission of all experimental studies, review articles and commentaries on this topic.
Dr. Zakir Khan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- angiotensin-converting enzyme 2
- Renin-Angiotensin System (RAS)
- coronavirus
- COVID-19
- infection
- health and diseases
- pathophysiology
- metabolism
- cardiovascular diseases
- hypertension
- diabetes
- neuropathology
